GSK to divest meningitis shots in exchange for EU clearance of Novartis deal

The European Commission has cleared GlaxoSmithKline's ($GSK) deal for most of Novartis' ($NVS) vaccines unit--on a couple of conditions. Glaxo has agreed to divest meningitis vaccines Nimenrix and Mencevax, marketed outside the U.S.; the duo generated £36 million ($54.7 million) in 2013. The British drugmaker will also part with two small bivalent vaccines sold in Italy and Germany that protect against diphtheria and tetanus, it said. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.